Decker Retirement Planning
ALNY icon

Decker Retirement Planning’s Alnylam Pharmaceuticals ALNY Stock Holding History

Decker Retirement Planning’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$247 Hold
1
– – ﹤0.01% 333
2026
Q2 		$301 Buy
+1
New +$302 ﹤0.01% 415

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

Decker Retirement Planning's ALNY Position: Q3 2026 in Review

Decker Retirement Planning held its Alnylam Pharmaceuticals (ALNY) position steady in Q3 2026 at 1 share worth $247. The position accounts for ﹤0.01% of the portfolio, ranked #333.

Decker Retirement Planning first reported a position in ALNY in Q2 2026 and has held it in 2 quarters since. The position peaked at $301 in Q2 2026. 497 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • Decker Retirement Planning held 1 share of Alnylam Pharmaceuticals worth $247 as of Q3 2026.
  • Decker Retirement Planning left its Alnylam Pharmaceuticals share count unchanged in Q3 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Decker Retirement Planning's portfolio in Q3 2026, its #333 holding.
  • Decker Retirement Planning first reported a position in Alnylam Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • Decker Retirement Planning's Alnylam Pharmaceuticals position peaked at $301 in Q2 2026.
  • 497 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Decker Retirement Planning's 13F filing for Q3 2026, filed 19 Oct 2026.